Study to Evaluate Changes in CD4 on Replacing TDF With ABC or DDI+TDF With ABC+3TC

PHASE3CompletedINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

April 30, 2005

Primary Completion Date

February 28, 2007

Study Completion Date

February 28, 2007

Conditions
HIV Infections
Interventions
DRUG

Abacavir

Change tenofovir to abacavir

DRUG

Didanosine

Increase didanosine dose to 400 mg/day if weight is \> 60 Kg. or to 250mg/day if weight is \< 60 kg.

DRUG

Abacavir+Lamivudine

Change tenofovir and didanosine to abacavir + lamivudine (600mg+300 mg/day in one single tablet).

Trial Locations (21)

11407

H. del S.A.S. Jerez de la Frontera, Jerez de la Frontera

12004

Hospital General de Castellón, , Castellón,, Castelló

15405

Hospital Arquitecto Marcide, Ferrol

18012

Hospital Clínico San Cecílio, Granada

28040

Fundación Jiménez Diaz, Madrid

Hospital Clínico San Carlos, Madrid

33394

Hospital de Cabueñes, Gijón

36204

Hospital Xeral de Vigo, Vigo

39008

Hospital Marqués de Valdecilla, Santander

39300

Hospital Sierrallana, Torrelavega

41009

Hospital Virgen Macarena, Seville

43007

Hospital Joan XXIII, Tarragona

46015

Hospital Arnau de Vilanova, Valencia

46700

H. San Fco Borja Gandia, Gandia

48013

Hospital Basurto, Bilbao

08916

Germans Trias i Pujol Hospital, Badalona

08025

Hospital de la Santa Creu i Sant Pau, Barcelona

08036

Hospital Clínic de Barcelona, Barcelona

08370

Hospital Sant Jaume de Calella, Calella

08304

Hospital de Mataró, Mataró

08400

Fundació Hospital de Granollers,, Barcelona

All Listed Sponsors
lead

Hospital de Granollers

OTHER

NCT00338390 - Study to Evaluate Changes in CD4 on Replacing TDF With ABC or DDI+TDF With ABC+3TC | Biotech Hunter | Biotech Hunter